RecruitingPhase 2NCT06315491
A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer
A Randomized Phase 2 Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer
Sponsor
Cybrexa Therapeutics
Enrollment
40 participants
Start Date
Sep 25, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to assess the safety, tolerability, and efficacy of CBX-12 in female subjects with platinum resistant or refractory ovarian cancer at 2 doses; 125 mg/m2 every 21 days or 100 mg/m2 every 21 days.
Eligibility
Sex: FEMALEMin Age: 18 Years
Inclusion Criteria9
- Subjects must have histologically- or cytologically-diagnosed epithelial high-grade serous cancer of the ovary, fallopian tube cancer or primary peritoneum cancer that is refractory to prior therapy and must have platinum-resistant disease defined as:
- Subjects who have received only 1 platinum-based chemotherapy regimen for at least 4 cycles of platinum must have disease progression on treatment or occurring ≤ 26 weeks after their last dose of platinum.
- Patients who have progressed following a second course of a platinum based regimen.
- Subjects may have up to 2 additional systemic regimens for advanced or metastatic disease. Maintenance regimens (e.g., with a PARP inhibitor or bevacizumab) are not considered separate regimens.
- Age greater than or equal to 18 years at the time of signing the informed consent form (ICF).
- Has measurable disease per RECIST 1.1.
- Has provided written informed consent.
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
- Adequate liver, renal, hematologic, pulmonary and coagulation function.
Exclusion Criteria5
- Cytotoxic chemotherapy, biologic agent, investigational agent, or radiation therapy within 3 weeks prior to the first dose of CBX-12.
- Subjects who are currently receiving any other anticancer or investigational agent(s).
- Clinically significant intercurrent disease.
- Active human immunodeficiency virus (HIV) infection.
- Active hepatitis B or C infection.
Interventions
DRUGCBX-12
CBX-12 is an alphalex construct which contains exatecan as the pharmacologically active moiety.
Locations(17)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06315491
Related Trials
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
NCT0528147131 locations
MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
NCT064830481 location
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
NCT0747085312 locations
A Study of Lorigerlimab in Participants With Advanced Solid Tumors
NCT0673034716 locations
Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer
NCT063214842 locations